Abstract Number: 0860 • ACR Convergence 2020
PREVAIL 1: A Multiple Ascending Dose Study in Normal Healthy Volunteers of PRV-3279, a Novel Bispecific DART Molecule Targeting CD32B and CD79B on B Cells, with Potential for Treatment of SLE
Background/Purpose: B-cell targeted therapeutics have proven efficacious in the treatment of autoimmune disorders. A desired improvement in efficacy and safety necessitate the development of alternate,…Abstract Number: 1094 • ACR Convergence 2020
Long Term Open Label Extension of Study of Tofacitinib in Refractory Dermatomyositis
Background/Purpose: Tofacitinib is a pan-JAK inhibitor that demonstrated safety and efficacy in a 12 week open label trial of 10 subjects with refractory dermatomyositis (NCT03002649).…Abstract Number: 1482 • ACR Convergence 2020
Joint Safety with Tanezumab: Integrated Analyses from Randomized Controlled Phase 3 Studies in Patients with Osteoarthritis
Background/Purpose: Tanezumab, a monoclonal antibody that inhibits nerve growth factor, has been shown effective in the management of osteoarthritis (OA) pain.1,2 Due to the potential…Abstract Number: 1843 • ACR Convergence 2020
Integrated Efficacy of the AURORA 1 and AURA-LV Trials Confirms Voclosporin Rapid Proteinurea Reduction in the Presence of Low-Dose Steroids
Background/Purpose: Voclosporin (VCS) is a novel calcineurin inhibitor (CNI) with a favorable metabolic profile and a consistent predictable dose response potentially eliminating the need for…Abstract Number: 0204 • ACR Convergence 2020
Pharmacokinetics and Safety of CT-P17, a Proposed High Concentration (100 mg/mL) Adalimumab Biosimilar, in Comparison with EU-Approved Adalimumab and US-Licensed Adalimumab; Results of a Phase 1, Randomized, Double-blind, Three-arm, Single-dose Study in Healthy Subjects
Background/Purpose: CT-P17 was developed as the first biosimilar of the high concentration (100 mg/mL), citrate-free formulation of reference adalimumab. The purpose of this study was…Abstract Number: 0237 • ACR Convergence 2020
Safety Profile of Upadacitinib up to 3 Years of Exposure in Patients with Rheumatoid Arthritis
Background/Purpose: The safety and efficacy of upadacitinib (UPA), an oral JAK inhibitor, was evaluated in the phase 3 SELECT clinical program, which included 5 randomized,…Abstract Number: 0546 • ACR Convergence 2020
Stepping up for Inflammatory Arthritis (SUFIA): A Pilot Trial to Test Behavioral Economics Strategy to Increase Physical Activity in Inflammatory Arthritis
Background/Purpose: Regular physical activity may have benefits for patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA), but patients with active disease are often reluctant…Abstract Number: 0862 • ACR Convergence 2020
Voclosporin Does Not Decrease Mycophenolic Acid Concentrations in Patients with SLE
Background/Purpose: Voclosporin (VCS) is a novel calcineurin inhibitor, structurally similar to cyclosporine A (CsA). In a Phase 3 clinical trial in patients with active lupus…Abstract Number: 1201 • ACR Convergence 2020
Effect of Filgotinib on Pain in Patients with Rheumatoid Arthritis: Results from Phase 3 Clinical Trials
Background/Purpose: RA patients (pts) often suffer substantial pain despite ongoing treatment (tx) and regard pain control as a top tx goal. Filgotinib (FIL)—a potent, oral…Abstract Number: 1490 • ACR Convergence 2020
Pain Rating Variability and Response to Treatment in Osteoarthritis Clinical Trials
Background/Purpose: Despite the known high inter- and intra-patient variability in analgesic responses in chronic pain, most interventional pain studies rely on single time point pain…Abstract Number: 1847 • ACR Convergence 2020
Delayed and Immediate Release Prednisone Decrease Fatigue Comparably in Patients with Systemic Lupus Erythematosus
Background/Purpose: Morning stiffness and fatigue are common symptoms in patients with SLE. Increased cytokines and disturbed sleep patterns may contribute to morning symptoms and fatigue…Abstract Number: 0207 • ACR Convergence 2020
Upadacitinib Monotherapy in Methotrexate-naïve Patients with Rheumatoid Arthritis: Results at 72 Weeks
Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor, demonstrated significant improvements in signs, symptoms, and structural inhibition as monotherapy vs methotrexate (MTX) in a randomized, controlled…Abstract Number: 0240 • ACR Convergence 2020
Long-term Safety and Efficacy of Sarilumab over 5 Years in Patients with Rheumatoid Arthritis with 1 or >1 Prior Tumor Necrosis Factor Inhibitor Failures
Background/Purpose: A proportion of adult patients with RA are refractory to TNF inhibitors (TNFi), and treatment with subsequent biologics may be associated with reduced response.…Abstract Number: 0572 • ACR Convergence 2020
Two-year Cost-effectiveness Between Two Gradual Tapering Strategies in Rheumatoid Arthritis: Cost-utility Analysis of the TARA Trial
Background/Purpose: The benefits of tapering are a decreased risk of long-term adverse events and a reduction of health care costs, especially when bDMARDs are tapered.…Abstract Number: 0866 • ACR Convergence 2020
Identifying an SLE Patient Cluster with Greater Treatment Effect: Immune Cell Deconvolution of Gene Expression in Two Atacicept Phase II Studies
Background/Purpose: Atacicept, a dual inhibitor of the B lymphocyte stimulator and a proliferation-inducing ligand (APRIL), has been associated with a reduction of flares in the…